Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Pharma

A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.

Partner, Health & Life Sciences, Oliver Wyman
Senior Knowledge Expert, Health & Life Sciences, Oliver Wyman

Our most popular articles of the year offered our predictions on disruption and the future market, and highlighted our views on healthcare reform, ACOs, and much more.

Purposeful collaboration will help more people understand how their daily decisions dictate their health.

Principal, Oliver Wyman

Advice on how the healthcare industry can address the pharmaceutical cost problem.

Principal, Oliver Wyman

In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman
Engagement Manager, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Partners Sam Glick and Sven-Olaf Vathje write in Harvard Business Review on how countries around the world can learn from a broken American healthcare system.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

What's around the bend for healthcare venture capital in 2018? We talk Amazon, good and bad M&A, and hitting the investment peak.

Senior Managing Director, GE Ventures

As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

How a “sticky” consumer experience could help control the drain of high-cost chronic disease drugs.

Partner, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe